Stallergenes Greer Announces Palforzia® Featured on "The Balancing Act" Airing on Lifetime TV
National Post4 days ago
Article content
National TV Segment Highlights FDA-Approved Oral Immunotherapy Treatment for Peanut Allergy
Article content
Segment premiered on Wednesday, July 30 and will be rebroadcast on Thursday, July 31, at 7:30 a.m. PT/ET
Article content
LENOIR, N.C. — Stallergenes Greer, a global leader in allergy therapeutics, today announced that a new segment of 'The Balancing Act ® ' airing on Lifetime TV featured its product Palforzia ® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first and only U.S. Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for peanut allergy in children ages 1 through 17 years. 1 The Stallergenes Greer sponsored segment premiered nationwide on Wednesday, July 30 at 7:30 a.m. (ET/PT) and features the story of a family with a peanut allergic child who was treated with Palforzia ® .
Article content
'We are proud to see Palforzia ® featured on 'The Balancing Act ®,' bringing national visibility to peanut allergy and a first of it's kind, FDA-approved oral immunotherapy treatment option for children and toddlers that can help to reduce the risk of life-threatening reactions that can occur with a peanut allergy,'
Article content
said Tibor Nemes, Executive Vice President, Head of Americas for Stallergenes Greer
Article content
. 'This segment is an opportunity to educate patients, caregivers and healthcare providers about Palforzia ®, and to further our commitment as Stallergenes Greer to provide innovative allergen immunotherapy (AIT) treatments to the allergy community that we serve.'
Peanut allergy currently affects approximately 2% of the US pediatric population 2-3 Compared to other food allergies, peanut allergy is associated with higher rates of morbidity due to accidental exposure 4. The severity of reactions in some patients despite strict allergen avoidance efforts highlights the need for safe and effective therapies. 5 The featured segment included insights shared by Pediatric Allergist and Immunologist, Panida Sriaroon, M.D., on food allergies and the challenges that some patients with food allergies and their families may face. Dr. Sriaroon, also presented Palforzia ® and its significance as the first and only FDA-approved oral immunotherapy treatment option available in the treatment landscape for peanut allergy.
Article content
Palforzia ® was first approved by the FDA in 2020, under Aimmune Therapeutics, Inc., as an oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut in children ages 4 through 17 years. In 2024, the FDA approved Palforzia ® for the expanded indication for toddler patients (ages 1 through 3 years) and the toddler product was launched in March 2025 by Stallergenes Greer.
Article content
In addition to the July 30 premiere, the featured segment on 'The Balancing Act' will be rebroadcast on Thursday, July 31, at 7:30 a.m. (ET/PT). It can also be viewed on the show's website TheBalancingAct.com. Palforzia ® is only available through a REMS (Risk Evaluation and Mitigation Strategy) program. Additional information about Palforzia ®, including Boxed Warning, full Prescribing Information and Medication Guide is available at www.Palforzia.com. *The participants featured in this segment were compensated for their time.
Article content
ABOUT PALFORZIA ®
Article content
Palforzia ® is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. Palforzia ® is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 1 to 17 years. Up-Dosing and Maintenance may be continued in patients 1 year of age and older.
Article content
Palforzia ® is to be used in conjunction with a peanut-avoidant diet.
Article content
Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis.
Article content
Palforzia ® is approved by the U.S. Food and Drug Administration (FDA) for ages 1 through 17 years.
Article content
WARNING: ANAPHYLAXIS: Palforzia ® can cause anaphylaxis, which may be life-threatening and can occur at any time during Palforzia ® therapy. Prescribe epinephrine, instruct and treat patients on its appropriate use, and instruct patients to see immediate medical care upon its use. Do not administer Palforzia ® to patients with uncontrolled asthma. Dose modifications may be necessary following a anaphylactic reaction. Observe patients during and after administration of the Initial Dose Escalation and the first dose of each Up-Dose level, for at least 60 minutes. Palforzia ® is available only through a restricted program called the Palforzia ® REMS.
Article content
is contraindicated in patients with uncontrolled asthma, or with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal diseases.
Article content
WARNINGS AND PRECAUTIONS: Anaphylaxis:
Article content
Palforzia
Article content
®
Article content
can cause anaphylaxis, which may be life-threatening. Palforzia
Article content
®
Article content
is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palforzia
Article content
®
Article content
REMS because of the risk of anaphylaxis. Only prescribers, healthcare settings, pharmacies, and patients certified and enrolled in the REMS Program can prescribe, receive, dispense or administer Palforzia
Article content
®
Article content
®
Article content
dosing, including Maintenance and in subjects who have undergone recommended Up-Dosing and dose modification procedures. Do not initiate Palforzia
Article content
®
Article content
treatment in a patient who has had severe or life-threatening anaphylaxis within the previous 60 days. Palforzia
Article content
®
Article content
may not be suitable for patients with certain medical conditions that may reduce the ability to survive anaphylaxis, including, but not limited to, markedly compromised lung function, severe mast cell disorder, or cardiovascular disease. In addition, Palforzia
Article content
®
Article content
may not be suitable for patients taking medications that can inhibit or potentiate the effects of epinephrine. All Initial Dose Escalation doses and the first dose of each Up-Dosing level must be administered under observation in a certified healthcare setting. Patients may be more likely to experience allergic reactions following Palforzia
Article content
®
Article content
administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (e.g., viral infection), or fasting. Other potential cofactors may include menstruation, sleep deprivation, nonsteroidal anti-inflammatory drug use, or uncontrolled asthma. Patients should be proactively counseled about the potential for the increased risk of anaphylaxis in the presence of these cofactors. If possible, adjust the time of dosing to avoid these cofactors. If it is not possible to avoid these cofactors, consider withholding Palforzia
Article content
®
Article content
temporarily.
Article content
Asthma:
Article content
®
Article content
. Palforzia
Article content
®
Article content
should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of Palforzia
Article content
®
Article content
®
Article content
.
Article content
Eosinophilic Gastrointestinal Disease:
Article content
Discontinue Palforzia
Article content
®
Article content
and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastrointestinal symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain.
Article content
Gastrointestinal Adverse Reactions:
Article content
®
Article content
-treated subjects, and dose modification should be considered for patients who report these reactions. For severe or persistent gastrointestinal symptoms, consider a diagnosis of eosinophilic esophagitis.
Article content
®
Article content
Article content
(incidence ≥5%) are cough, sneezing, rhinitis, nasal congestion, throat irritation, wheezing, abdominal pain, vomiting, diarrhea, oral pruritus, oropharyngeal pain, urticaria, rash, pruritus, and perioral dermatitis. The most common adverse reactions reported in subjects ages 4 through 17 years treated with Palforzia
Article content
®
Article content
(incidence ≥5% and at least 5% greater than placebo) are abdominal pain, vomiting, nausea, oral pruritus, oral paresthesia, throat irritation, cough, rhinorrhea, sneezing, throat tightness, wheezing, dyspnea, urticaria, anaphylactic reaction, and ear pruritus.
Article content
ABOUT THE BALANCING ACT
Article content
The Balancing Act ® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime ® and find all previously aired episodes on TheBalancingAct.com. ABOUT STALLERGENES GREER Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries.
Article content
PALFORZIA [package insert]. Lenoir, NC; Greer Laboratories, Inc.
Article content
2
Article content
Bilaver LA, Chadha AS, Doshi P, O'Dwyer L, Gupta RS. Economic burden of food allergy: A systematic review. Ann Allergy Asthma Immunol 2019;122:373–80 e1.
Article content
3
Article content
Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011;128:e9–17.
Article content
4
Article content
The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online:
Article content
. Accessed August 31, 2023
Article content
Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Stallergenes Greer USA
Article content
Article content
Article content
National TV Segment Highlights FDA-Approved Oral Immunotherapy Treatment for Peanut Allergy
Article content
Segment premiered on Wednesday, July 30 and will be rebroadcast on Thursday, July 31, at 7:30 a.m. PT/ET
Article content
LENOIR, N.C. — Stallergenes Greer, a global leader in allergy therapeutics, today announced that a new segment of 'The Balancing Act ® ' airing on Lifetime TV featured its product Palforzia ® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first and only U.S. Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for peanut allergy in children ages 1 through 17 years. 1 The Stallergenes Greer sponsored segment premiered nationwide on Wednesday, July 30 at 7:30 a.m. (ET/PT) and features the story of a family with a peanut allergic child who was treated with Palforzia ® .
Article content
'We are proud to see Palforzia ® featured on 'The Balancing Act ®,' bringing national visibility to peanut allergy and a first of it's kind, FDA-approved oral immunotherapy treatment option for children and toddlers that can help to reduce the risk of life-threatening reactions that can occur with a peanut allergy,'
Article content
said Tibor Nemes, Executive Vice President, Head of Americas for Stallergenes Greer
Article content
. 'This segment is an opportunity to educate patients, caregivers and healthcare providers about Palforzia ®, and to further our commitment as Stallergenes Greer to provide innovative allergen immunotherapy (AIT) treatments to the allergy community that we serve.'
Peanut allergy currently affects approximately 2% of the US pediatric population 2-3 Compared to other food allergies, peanut allergy is associated with higher rates of morbidity due to accidental exposure 4. The severity of reactions in some patients despite strict allergen avoidance efforts highlights the need for safe and effective therapies. 5 The featured segment included insights shared by Pediatric Allergist and Immunologist, Panida Sriaroon, M.D., on food allergies and the challenges that some patients with food allergies and their families may face. Dr. Sriaroon, also presented Palforzia ® and its significance as the first and only FDA-approved oral immunotherapy treatment option available in the treatment landscape for peanut allergy.
Article content
Palforzia ® was first approved by the FDA in 2020, under Aimmune Therapeutics, Inc., as an oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut in children ages 4 through 17 years. In 2024, the FDA approved Palforzia ® for the expanded indication for toddler patients (ages 1 through 3 years) and the toddler product was launched in March 2025 by Stallergenes Greer.
Article content
In addition to the July 30 premiere, the featured segment on 'The Balancing Act' will be rebroadcast on Thursday, July 31, at 7:30 a.m. (ET/PT). It can also be viewed on the show's website TheBalancingAct.com. Palforzia ® is only available through a REMS (Risk Evaluation and Mitigation Strategy) program. Additional information about Palforzia ®, including Boxed Warning, full Prescribing Information and Medication Guide is available at www.Palforzia.com. *The participants featured in this segment were compensated for their time.
Article content
ABOUT PALFORZIA ®
Article content
Palforzia ® is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. Palforzia ® is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 1 to 17 years. Up-Dosing and Maintenance may be continued in patients 1 year of age and older.
Article content
Palforzia ® is to be used in conjunction with a peanut-avoidant diet.
Article content
Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis.
Article content
Palforzia ® is approved by the U.S. Food and Drug Administration (FDA) for ages 1 through 17 years.
Article content
WARNING: ANAPHYLAXIS: Palforzia ® can cause anaphylaxis, which may be life-threatening and can occur at any time during Palforzia ® therapy. Prescribe epinephrine, instruct and treat patients on its appropriate use, and instruct patients to see immediate medical care upon its use. Do not administer Palforzia ® to patients with uncontrolled asthma. Dose modifications may be necessary following a anaphylactic reaction. Observe patients during and after administration of the Initial Dose Escalation and the first dose of each Up-Dose level, for at least 60 minutes. Palforzia ® is available only through a restricted program called the Palforzia ® REMS.
Article content
is contraindicated in patients with uncontrolled asthma, or with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal diseases.
Article content
WARNINGS AND PRECAUTIONS: Anaphylaxis:
Article content
Palforzia
Article content
®
Article content
can cause anaphylaxis, which may be life-threatening. Palforzia
Article content
®
Article content
is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palforzia
Article content
®
Article content
REMS because of the risk of anaphylaxis. Only prescribers, healthcare settings, pharmacies, and patients certified and enrolled in the REMS Program can prescribe, receive, dispense or administer Palforzia
Article content
®
Article content
®
Article content
dosing, including Maintenance and in subjects who have undergone recommended Up-Dosing and dose modification procedures. Do not initiate Palforzia
Article content
®
Article content
treatment in a patient who has had severe or life-threatening anaphylaxis within the previous 60 days. Palforzia
Article content
®
Article content
may not be suitable for patients with certain medical conditions that may reduce the ability to survive anaphylaxis, including, but not limited to, markedly compromised lung function, severe mast cell disorder, or cardiovascular disease. In addition, Palforzia
Article content
®
Article content
may not be suitable for patients taking medications that can inhibit or potentiate the effects of epinephrine. All Initial Dose Escalation doses and the first dose of each Up-Dosing level must be administered under observation in a certified healthcare setting. Patients may be more likely to experience allergic reactions following Palforzia
Article content
®
Article content
administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (e.g., viral infection), or fasting. Other potential cofactors may include menstruation, sleep deprivation, nonsteroidal anti-inflammatory drug use, or uncontrolled asthma. Patients should be proactively counseled about the potential for the increased risk of anaphylaxis in the presence of these cofactors. If possible, adjust the time of dosing to avoid these cofactors. If it is not possible to avoid these cofactors, consider withholding Palforzia
Article content
®
Article content
temporarily.
Article content
Asthma:
Article content
®
Article content
. Palforzia
Article content
®
Article content
should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of Palforzia
Article content
®
Article content
®
Article content
.
Article content
Eosinophilic Gastrointestinal Disease:
Article content
Discontinue Palforzia
Article content
®
Article content
and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastrointestinal symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain.
Article content
Gastrointestinal Adverse Reactions:
Article content
®
Article content
-treated subjects, and dose modification should be considered for patients who report these reactions. For severe or persistent gastrointestinal symptoms, consider a diagnosis of eosinophilic esophagitis.
Article content
®
Article content
Article content
(incidence ≥5%) are cough, sneezing, rhinitis, nasal congestion, throat irritation, wheezing, abdominal pain, vomiting, diarrhea, oral pruritus, oropharyngeal pain, urticaria, rash, pruritus, and perioral dermatitis. The most common adverse reactions reported in subjects ages 4 through 17 years treated with Palforzia
Article content
®
Article content
(incidence ≥5% and at least 5% greater than placebo) are abdominal pain, vomiting, nausea, oral pruritus, oral paresthesia, throat irritation, cough, rhinorrhea, sneezing, throat tightness, wheezing, dyspnea, urticaria, anaphylactic reaction, and ear pruritus.
Article content
ABOUT THE BALANCING ACT
Article content
The Balancing Act ® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime ® and find all previously aired episodes on TheBalancingAct.com. ABOUT STALLERGENES GREER Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries.
Article content
PALFORZIA [package insert]. Lenoir, NC; Greer Laboratories, Inc.
Article content
2
Article content
Bilaver LA, Chadha AS, Doshi P, O'Dwyer L, Gupta RS. Economic burden of food allergy: A systematic review. Ann Allergy Asthma Immunol 2019;122:373–80 e1.
Article content
3
Article content
Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011;128:e9–17.
Article content
4
Article content
The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online:
Article content
. Accessed August 31, 2023
Article content
Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Stallergenes Greer USA
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
7 hours ago
- CBC
New study looks at teen loneliness and AI: Dr. Peter Lin
A recent study by Common Sense Media and the University of Chicago asked teens about their use of artificial intelligence. Dr. Peter Lin explains what the study showed and how AI is affecting the mental health of teenagers.
CBC
a day ago
- CBC
Expert discusses potential impact of Trump's demand to slash drug prices in U.S.
U.S. President Donald Trump has issued a direct warning to top pharmaceutical companies, demanding they slash drug prices. Mina Tadrous, an associate professor at the University of Toronto's Leslie Dan Faculty of Pharmacy, discusses concerns and how this could impact drug prices in Canada.
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.
